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Background: New chemotherapic agents and new protocols in oncology have led to an increasing survival rate in
patients affected by tumors. However, this increased use has been accompanied by a growth in the incidence of
cutaneous side effects and a worsening of patients’ quality of life. Appropriate management of skin toxicity
associated with chemotherapic agents is therefore necessary for suitable drug administration and to improve
quality of life and clinical outcomes.
Methods: We have clinically examined 100 patients affected by cancer, determining type, frequency, treatment,
and evolution of side effects related to chemotherapy.
Results: The prevalent cutaneous side effects in patients undergoing chemotherapy are skin rash, xerosis, pruritus,
paronychia, hair abnormality, and mucositis. The clinical cases are reported in detail.
Conclusion: Oncological therapies have become more selective and have low systemic toxicity because of their
high specificity, but cutaneous side effects are common and may worsen the quality of life of these patients.
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Over the last two decades, a number of new chemother-
apeutic agents have been used for the treatment of
cancer.
These drugs may be classified according to their mechan-
ism of action in: Signal transduction inhibitors (Epidermal
growth factor receptor – EGFR- antagonists and Multiki-
nase inhibitors), Proteasome inhibitors, Spindle inhibitors
(Taxanes and Vinca alkaloids), Antimetabolites (Purine ana-
logs and Pyrimidine analogs), Genotoxic agents [1].
Chemotherapeutic agents have significant side effects.
Although skin toxicity is rarely life-threatening it often
worsens the patients’ quality of life.
It is well known that, cytotoxic agents like Cyclophospha-
mide, Chlorambucil, Busulfan, Procarbazine can cause side-
effects on hair and nails (alopecia, paronychia, melanony-
chia, and other abnormalities), on skin barrier (skin rash,
skin dryness, hyperpigmentation) and on mucose (Steven-
Johnson Syndrome and toxic epidermic necrolysis).
In recent years, targeted therapy has considerably
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distribution, and reproduction in any mediumsolid tumors of kidney, lungs, colon-rectum, breast and
liver. Among the innovative therapeutic strategies in
chemotherapy, the EGFR inhibitors (Cetuximab, Panitu-
mumab, Erlotinib, Gefitinib) approved for lung and
colon-rectum tumors showed an increasing skin toxicity,
causing widespread skin dryness (in more than 90% of
patients) and a follicular rash which can be complicated
by pruritus, pain and infections [2,3]
Despite the benefits of all these chemotherapic agents,
toxic effects on the skin may eventually result in poor
compliance of patients and interruptions or discontinu-
ation of antineoplastic therapy [4,5]. Such toxic effects
of the skin may also significantly reduce the quality of
life of oncological patients .
The aim of our study is to present all cases of muco-
cutaneous side effect of these new drugs referring to 3
outpatient departments for the skin care of oncological
patients in Naples and Rome from October 2010
through December 2011.Methods
From October 2010, 3 outpatient departments for the skin
care of oncological patients have been set up: the Depart-
ment of Dermatology at the University Federico II intral Ltd. This is an Open Access article distributed under the terms of the
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ASL Roma C in Rome. We have collected data from the
outpatient departments of these Dermatological Units of
100 patients in chemo and radiotherapy (35 males and 65
females), aged from 24 to 80 years (mean age 58± 7,5). We
included in the study patients in chemotherapy of both
sex, suffering from mucocutaneous side effects which had
begun after the first administration of the drug. We
excluded patients under radiotherapy and patients in
which mucocutaneous symptoms were already present at
the beginning of chemotherapy. Every side effect has been
evaluated by Common Terminology Criteria for Adverse
Events (CTCAE) version 4.03 [6]. The patients’ data has
been registered using a software set up specifically to rec-
ord the patients’ general information, tumor grading, type
of chemotherapy. Moreover skin of patients affected by
dry skin and skin rashes was instrumentally evaluated by
corneometry, trans-epidermal water loss (TEWL) and
colorimetry.
Corneometry evaluation has been performed using the
Corneometer CM 820 PC Courage (Courage +Khazaka
electronic Mathias-Brüggen-Str. 91 D-50829 Köln (Ger-
many)), which measures skin conductance through low
intensity electric current. This value is inversely related
to skin water content of the stratum corneum and gives
a direct measurement of skin hydration units.
The Tewameter device (Tewameter TM 210 Courage –
Khazaka electronic) measures the amount of transepider-
mal water loss (TEWL) and has been used to determine
skin hydration grade with moisture and temperature
sensors.
Colorimetry analysis has been performed by Spectroco-
lorimeter (X-Rite), whose special probe makes it possible
to evaluate skin color according to the L* a* b* para-
meters. We have considered only the L* value, which
represents the relative brightness between total black and
total white.
Different dermocosmetical therapies were performed
on the basis of different mucocutaneous reactions.
Patients were observed at time 0 (first visit) and time 30
(after 30 days). We also performed χ2 square test to
compare different adverse drug reactions and type of
drugs administred.
This study has been performed with the approval of
the Institutional Review Board of Department of Derma-
tology, University of Naples “Federico II”. It is in compli-
ance with the Helsinki Declaration.
Results
Samples were collected from 100 patients affected by:
breast cancer (45 patients), colon-rectal cancer (10
patients), lung cancer (10 patients), prostate (4 patients),
Hodgkin’s lymphoma HL (4 patients), stomach cancer (4
patients), thyroid cancer (4 patients), leukaemia (3 patients),Non-Hodgkin lymphomas NHL (3 patients), ovary cancer
(2 patients), uterus cancer (2 patients), liver cancer (2
patients), kidney cancer (2 patients), oesophagus cancer (2
patients), neuroendocrine cancer (2 patients), schwannoma
(1 patient).
Thirty-four of our patients were under treatment with
EGFR-inhibitors and in particular with Cetuximab, Erlo-
tinib, Lapatinib, Gefitinib and Panitumumab; 23 patients
underwent hormonal therapy; 17 patients were in ther-
apy with traditional drugs (i.e. Genotoxic agents Spindle
inhibitors, Antimetabolites).
In the EGFR-inhibitors group we observed 19 papulo-
pustular reactions (55.88% of patients). 14 patients
showed dry skin (41.17%) and 10 nail alterations
(29.41%). Only 6 patients (17.64%) suffered from hair al-
teration including alopecia and anagen effluvium (Add-
itional files 1 and 2).
Patients under hormonal therapy mostly suffered from
dry skin (14 patients, 60.86%). In this group we also
observed hair alterations (5 patients, 21.73%) and nail
alterations (6 patients, 26.08%) (Additional file 2 and 3).
Patients who had assumed traditional drugs showed
dry skin (10 patients, 58.82%) and hair and nail altera-
tions (6 and 4 patients respectively, 35.29% and 23.59%)
(Additional file 2 and 4).
The χ2 square test we performed to evaluate different
EGFR-inhibitor molecules showed a higher prevalence of
follicular reactions induced by antibodies (Cetuximab
and Panitunumab) in comparison with small molecules
(Erlotinib, Gefitinib and Lapatinib) p <0,005. Occur-
rence of xerosis instead was higher with hormonal ther-
apy than with EGFR-inhibitors p< 0.005.
In accordance with the current literature the follicular
rash (Figures 1 and 2) usually occurred a few days after
administration of the drug and reached a maximum after
2–3 weeks. The skin lesions consist of erythematous fol-
licular papules that may evolve into pustules, localized
on the face, neck and retroauricular area, scalp and
upper trunk.
Nail alterations, consisting mostly in frailer nails and
paronychia (Figure 3) were often associated with painful
fissures of the fingertips (Figure 4).
All the patients with xerosis and skin rashes were in-
strumentally evaluated by Corneometer, Tewameter and
Spectrocolorimeter to study the correlation between
such cutaneous toxicities and skin hydration, skin barrier
function and skin brightness at the baseline and during
cutaneous therapy. Corneometry examination showed
average values between 0 and 50 in all the patients
examined, which indicated high skin dehydration at the
baseline (T0). A high majority of subjects also had signs
of skin barrier function damage indicated by the Tewa-
meter measurement (average values: 16.67 g/m2h) and
low brightness values (L*). The dermatologic therapy
Figure 1 Panitunumab-related follicular rash.
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Corneometer and Tewameter value.
Discussion
Signal transduction inhibitors, in particular EGFR-
antagonists, are a new class of chemotherapic agents,
whose side effects result to be in dermatologic clinical
practice [4,5].The most frequently reported toxic cutaneous effect
deriving from these drugs is the papulo-pustular follicu-
lar rash, which is defined as a form of acne since it
involves above all the face’s seborrhoeic areas, scalp and
chest and less frequently the extremities and the back.
Such an eruption appears during the first two weeks of
treatment [2,3], accompanied by an extremely irritating
pruritus and can be complicated by bacterial over-
Figure 2 Follicular rash induced by Cetuximab.
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the association of a typical sebaceous gland disease with
a marked xerosis, indicating that the main pathogenetic
factor is not the cutaneous adnexa but the keratinocyte
itself.
The EGFR receptor is expressed in the basal layer of
the epidermis and promotes the differentiation of kerati-
nocytes and follicular cells. Moreover, EGFR-inhibitors
inhibit not only the EGFR when overexpressed in tumor
cells, but also the receptor present on normal cells of
the epidermis. The inhibition of EGFR in normal skin
leads to alterations of growth and migration of keratino-
cytes that, together with inflammatory reactions, lead to
xerosis and papulopustolar skin rash. Mucosa and cutis
xerosis, varying from light to more severe forms with ec-
zema and fissures, has so far shown a variable incidence
from 12% to 35% in clinical trials [7,8] and it often
represents one of the cutaneous parameters persistently
influencing the patient’s quality of life.
Nail alterations are frequently connected to the use of
EGFR-inhibitors. The pathogenesis is unknown but it
might be related to increased skin fragility induced by
the treatment [2]. The clinical manifestation may be par-
onychia or periungual abscesses, which are usually a late
sign of toxicity with an onset of about two months from
beginning of the therapy. The first lesions are usually
localized on the big toe. The toes present a very painful
erythema.
Antimetabolites, 5-FU and Capecitabine in particular,
result in a distinctive sign of toxicity: hand-foot syn-
drome, more frequent with Capecitabine. Patients can
show erythema and swelling in mild cases, or in severe
cases, blisters ulceration and desquamation. Patients alsorefer numbness and paraesthesia. Lesions are located on
the palms of hands and soles of the feet. Another sign of
skin toxicity linked to the use of Capecitabine is hyper-
pigmentation. This abnormality is also observed with
Cyclophosphamide and Doxorubicin [9-12]. Patients can
present black longitudinal pigmentation of the nails
without any symptoms. These drugs are also connected
to focal skin pigmentation, mainly involving the finger-
tips, combined with paresthesia or pain. According to
some authors these manifestations may be considered as
initial signs of the hand-foot syndrome [10]. The exact
pathogenesis is unknown but it may be related to the
increased expression in the skin of the fingertips of the
enzymes necessary for Capecitabine activation in 5-FU.
Damage of the nerve fibres seems to be the cause of the
neuropathic symptoms [10].
Spindle inhibitors, i.e. Vinca alkaloids and Taxanes,
approved for many solid and hematological tumors, are
strictly related to alopecia and other skin diseases such
as dermatitis, radiation recall, subacute cutaneous lupus
erythematosus, nail abnormalities and ulcerations caused
by extravasation, this reaction in particular is caused by
direct damage to soft tissue.
Genotoxic agents may cause severe, well-known, aller-
gic IgE-mediated reactions, in particular Platinum agents
but also antibiotics. These can also lead to alopecia, be-
cause of their targeting on proliferating cells, and par-
ticular effects like erythema flagellatum whose
pathogenesis is unknown.
Multikinase inhibitors used in hematology like Imati-
nib, Dasatinib and Nilotinib seem to be connected to
frequent skin toxicity mainly consisting of dermatitis,
sometimes exfoliative, associated with fever [1] and
Figure 3 Paronychia in a female patient treated with Lapatinib.
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other multikinase inhibitors used for kidney and liver
cancer. Inflammatory actinic keratosis has also been
observed [13,14].
Sunitinib is associated to bullous manifestation and
hand-foot syndrome, which can also be used as a marker
of drug efficacy [15].Figure 4 Fissures of the fingertips in a patient treated with taxanes.Conclusions
New drugs and new therapeutic schedules have brought
many malignancies to a better prognosis and a longer
survival. However newer drugs, in particular targeted
therapies, often provoke side effects on the skin, obliging
physicians to suspend therapy. For this reason the chal-
lenge of future studies in this field is to identify methods
capable to prevent this kind of side effects and, at the
same time, specific therapies for each skin problem. Co-
operation between oncologists and dermatologists is also
fundamental in order to make the best decisions for the
patients and to implement preventive measures.
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